bankruptcy

Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests. 

The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.

Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.

True Health made its bid last week in an auction, increasing it from an original $32 million in order to beat out other potential buyers.

True Health will pay $37.1 million to acquire substantially all the assets of Health Diagnostic Laboratory, which is currently in Chapter 11 reorganization. 

True Health seeks to acquire substantially all the assets of Health Diagnostics Laboratory, which filed for Chapter 11 bankruptcy protection in June.

As part of the settlement reached with the agency, NMT will also cease all operations, end its plans to reorganize, and liquidate its assets. 

ZyGem LLC, a former US subsidiary of New Zealand-based biotech firm ZyGem Limited, is no longer in business after a group of former employees and contractors earlier this year filed a petition with a federal court to force the company into Chapter 7 bankruptcy for debts owed,

Pages

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.